Curik, N <br/><br/>
5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.  [electronic resource] 

 -  Leukemia  Aug 2012 
 - 1804-11 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2012.47  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antimetabolites, Antineoplastic--pharmacology<br/>Azacitidine--pharmacology<br/>Cell Differentiation--drug effects<br/>Cell Line, Tumor<br/>Chromatin--genetics<br/>Colony-Stimulating Factors--pharmacology<br/>DNA Methylation--drug effects<br/>Female<br/>Gene Expression Regulation, Leukemic--drug effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Myelodysplastic Syndromes--drug therapy<br/>Neoplastic Stem Cells--cytology<br/>Proto-Oncogene Proteins--genetics<br/>Regulatory Sequences, Nucleic Acid--drug effects<br/>Trans-Activators--genetics<br/>Transcriptional Activation--drug effects